Similarly, Sakai et al. [37] reported acquired resistance to cisplatin and PARP-is in BRCA2 breast and pancreatic cancer cell lines through acquisition of secondary genetic events restoring wild-type BRCA2 function. This evidence concerns the gene BRCA2 and pancreatic neoplasm.